Company intelligence / Profile preview
Merck & Co.
Rahway, New Jersey, United Statesmerck.com ↗
- Ownership
- Public · MRK
- Employees
- ~68000
- Development stage
- Other
01
Overview
Merck has a diverse pipeline with multiple commercial products. Their flagship product Keytruda faces patent expiration, but they have seven potential cardiometabolic approvals anticipated by 2030 with peak revenue potential exceeding $15 billion by mid-2030s. Recently approved Winrevair for pulmonary arterial hypertension showed strong efficacy.
- Therapeutic areas
- OphthalmologyOncologyCardiovascular
- Modalities
- Small moleculesbiologicsvaccines
- Industry
- Pharma
02
Drug pipeline
830 assets829 more assets in the full pipeline.
03
Financials
- Market cap
- $362.5B
- Total revenue
- $64.9B
- Enterprise value
- $406.7B
Beyond the preview
Go deeper on Merck & Co..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merck & Co..